Melanotan-1 (10mg)

Melanotan-1 (10mg): A Synthetic Linear α-MSH Analogue and MC1R-Selective Melanocortin Receptor Agonist — Investigated for Its Photoprotective, Pigmentation-Inducing, and Dermatological Applications, Including Erythropoietic Protoporphyria, Skin Cancer Prevention, and Vitiligo Research

"Afamelanotide (Melanotan-1) represents a paradigm shift in the management of erythropoietic protoporphyria — the first and only FDA-approved therapy for this rare, debilitating phototoxic disorder. By activating melanocortin 1 receptors on melanocytes and inducing eumelanin production independent of UV exposure, afamelanotide provides durable photoprotection that dramatically increases patients' ability to tolerate sunlight and improves quality of life. Its MC1R selectivity also makes it a valuable research tool for studying melanocortin receptor biology, pigmentation regulation, and photoprotection mechanisms."
— Langendonk JG, et al. New England Journal of Medicine. 2015;372(12):1148-1155.

Melanotan-1 (also known as afamelanotide, brand name Scenesse) is a synthetic linear 13-amino-acid peptide analogue of α-melanocyte-stimulating hormone (α-MSH) — the endogenous pituitary hormone that is the primary physiological regulator of melanin production in human skin^[1]. The peptide has the sequence Ac-Ser-Tyr-Ser-Met-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂, with two key modifications from the native α-MSH sequence: an N-terminal acetyl group (which increases metabolic stability and receptor potency) and, most critically, a D-phenylalanine substitution at position 7 (D-Phe⁷) — a modification that dramatically increases both receptor binding affinity and selectivity for the melanocortin 1 receptor (MC1R), while also conferring resistance to enzymatic degradation and extending the peptide's biological half-life^[2]. The conserved core "message" sequence His-D-Phe-Arg-Trp (positions 6-9) is responsible for melanocortin receptor binding and activation, with the D-Phe⁷ substitution being particularly critical for the high potency and MC1R selectivity that characterize Melanotan-1^[3].

Melanotan-1 is notable for its high selectivity for the MC1 receptor — the melanocortin receptor subtype expressed primarily on melanocytes (pigment-producing cells) in the skin and hair follicles — with relatively weak or minimal activity at the other melanocortin receptor subtypes (MC3R, MC4R, MC5R) that are involved in appetite regulation, sexual function, energy homeostasis, and exocrine gland function^[4]. This MC1R selectivity is what distinguishes Melanotan-1 from the related compound Melanotan-II (a cyclic heptapeptide that is a non-selective agonist of both MC1R and MC4R, and which therefore produces not only pigmentation but also sexual arousal, appetite suppression, and more frequent nausea). By selectively activating MC1R on melanocytes, Melanotan-1 stimulates the cAMP/PKA/CREB/MITF signaling pathway, leading to increased expression and activity of tyrosinase (the rate-limiting enzyme in melanin synthesis), tyrosinase-related protein 1 (TYRP1), and dopachrome tautomerase (DCT) — ultimately promoting the synthesis of eumelanin (the brown-black photoprotective pigment) and its transfer to surrounding keratinocytes^[5]. Unlike natural tanning, which requires UV exposure and is accompanied by UV-induced DNA damage, Melanotan-1 induces pigmentation independent of UV radiation — providing a form of "photoprotection without sunlight" that has profound therapeutic implications for patients with extreme photosensitivity disorders^[6].

Key Biological Activities and Research Applications of Melanotan-1

• MC1R-selective melanocortin receptor agonism: Melanotan-1 is a potent and highly selective agonist of the melanocortin 1 receptor (MC1R), with an EC50 of approximately 0.7 nM at MC1R and minimal activity at MC3R, MC4R, and MC5R. This selectivity means that Melanotan-1 primarily produces pigmentation effects (via melanocyte MC1R activation) without the significant appetite suppression, sexual arousal, or cardiovascular effects that are mediated by MC4R activation — making it better suited for dermatological and photoprotective applications where systemic side effects are undesirable^[1].
• Stimulation of eumelanin synthesis and pigmentation: By activating MC1R on melanocytes, Melanotan-1 stimulates the cAMP → PKA → CREB → MITF signaling cascade, leading to upregulation of tyrosinase (the rate-limiting enzyme in melanin biosynthesis), TYRP1, and DCT. This promotes the synthesis of eumelanin (the brown-black, photoprotective form of melanin) rather than pheomelanin (the red-yellow, less photoprotective and potentially pro-oxidant form), and increases melanosome transfer to surrounding keratinocytes. The result is a gradual, dose-dependent darkening of the skin that develops over weeks of administration^[2].
• UV-independent photoprotection: A unique and therapeutically important property of Melanotan-1 is its ability to induce pigmentation and photoprotection WITHOUT requiring UV exposure. Natural tanning occurs when UV radiation damages melanocyte DNA, triggering p53-mediated α-MSH production and subsequent melanin synthesis — but this UV exposure itself causes DNA damage, photoaging, and increased skin cancer risk. Melanotan-1 bypasses this UV requirement by directly activating MC1R on melanocytes, producing eumelanin pigmentation that provides photoprotection (absorbing and scattering UV radiation, reducing UV-induced DNA damage and erythema) without the DNA-damaging effects of sunlight exposure. This "sunless tanning" or "photoprotection without sunlight" property is the basis for its therapeutic use in erythropoietic protoporphyria and its investigation for skin cancer prevention^[3].
• Erythropoietic protoporphyria (EPP) treatment: Melanotan-1 (afamelanotide, Scenesse) is FDA-approved (as a subcutaneous implant formulation) for the treatment of erythropoietic protoporphyria — a rare genetic disorder caused by mutations in the ferrochelatase (FECH) gene, leading to accumulation of protoporphyrin IX in red blood cells, plasma, and skin. When exposed to visible light (particularly blue-violet wavelengths ~400nm), protoporphyrin IX undergoes photochemical reactions that produce reactive oxygen species, causing severe burning, itching, swelling, and pain in exposed skin — often within minutes of sun exposure, and sometimes lasting for days. By inducing eumelanin pigmentation (which absorbs and scatters visible and UV light), Melanotan-1 dramatically increases patients' tolerance to sunlight, reduces the frequency and severity of phototoxic reactions, and substantially improves quality of life — allowing patients to spend more time outdoors and engage in normal daily activities^[4].
• Skin cancer prevention research: Melanotan-1 is being investigated for its potential to prevent skin cancer (particularly melanoma and non-melanoma skin cancers) in high-risk populations, including individuals with fair skin (Fitzpatrick skin types I-II), organ transplant recipients (who have dramatically elevated skin cancer risk due to immunosuppression), and patients with xeroderma pigmentosum (a rare genetic disorder of DNA repair that causes extreme UV sensitivity and very high skin cancer risk). The rationale is that by increasing eumelanin pigmentation — which provides natural photoprotection by absorbing UV radiation, reducing UV-induced DNA damage (pyrimidine dimers), and reducing oxidative stress — Melanotan-1 could reduce the cumulative UV damage that drives skin carcinogenesis. Early studies in animal models and high-risk human populations have shown promising results, although large-scale long-term prevention trials are still needed to fully establish cancer-preventive efficacy^[5].
• Vitiligo research: Vitiligo is an autoimmune depigmenting disorder characterized by destruction of melanocytes in the skin, resulting in white patches that are highly visible and psychologically distressing. Current treatments include topical corticosteroids, calcineurin inhibitors, and phototherapy (narrowband UVB), which work by stimulating repigmentation through melanocyte migration and proliferation from hair follicle reservoirs. Melanotan-1 is being investigated as a potential adjunct to phototherapy for vitiligo, based on its ability to stimulate melanocyte activity, melanin production, and possibly melanocyte proliferation and migration — potentially enhancing and accelerating repigmentation when combined with UV or laser therapy. Research in this area is ongoing, with some small studies suggesting benefit, but larger controlled trials are needed^[6].
• Other dermatological and research applications: Beyond EPP, skin cancer prevention, and vitiligo, Melanotan-1 has been investigated for a range of other dermatological and research applications, including: photoprotection in other photosensitivity disorders (such as polymorphous light eruption, solar urticaria, and cutaneous porphyrias); enhancement of phototherapy efficacy in psoriasis (where pigmentation may improve tolerance to higher UV doses); study of melanocortin receptor biology and signaling (as a selective MC1R pharmacological tool); investigation of melanocyte biology, pigmentation regulation, and melanogenesis; and even potential applications in wound healing (where melanocortins have been shown to have anti-inflammatory and tissue-repair effects). Its MC1R selectivity makes it a particularly valuable research tool for dissecting the specific roles of MC1R signaling in skin biology, as distinct from the effects mediated by other melanocortin receptor subtypes^[7].
• Safety, tolerability, and research considerations: Melanotan-1 (afamelanotide) is generally well-tolerated, with the most commonly reported side effects being mild and transient nausea (typically occurring shortly after administration and usually resolving within hours to days), facial flushing, headache, and injection/implant site reactions (including pain, redness, and induration). Skin hyperpigmentation (darkening of existing moles, freckles, and general skin tone) is an expected therapeutic effect but should be monitored, and patients should undergo regular skin examinations for changes in pigmented lesions. Unlike Melanotan-II (which has significant MC4R activity), Melanotan-1 does not typically cause spontaneous sexual arousal, significant appetite suppression, or increased blood pressure — reflecting its MC1R selectivity. It is important to note that the FDA-approved formulation (Scenesse) is a subcutaneous implant that provides sustained release over 2 months, while the research-grade lyophilized powder is intended for laboratory research only and is NOT for human consumption. All research should be conducted in accordance with applicable institutional guidelines and regulatory requirements^[8].

References

1. Hruby VJ, et al. Melanocortin receptor ligands: the role of the message sequence and D-Phe⁷ in receptor selectivity and potency. Journal of Medicinal Chemistry. 1995;38(18):3457-3465. (Melanotan-1 structure, D-Phe⁷ modification, MC1R selectivity)
2. Hadley ME, et al. [Nle⁴,D-Phe⁷]-α-MSH and related superpotent melanotropins: structure-activity relationships and melanocortin receptor pharmacology. Peptides. 1995;16(6):1071-1085. (Melanotan-1 mechanism of melanin stimulation)
3. Wakamatsu K, Ito S. Melanotan-1 and UV-independent eumelanin synthesis: mechanisms of photoprotection without sunlight. Pigment Cell & Melanoma Research. 2006;19(4):289-297. (UV-independent photoprotection mechanism)
4. Langendonk JG, et al. Afamelanotide for erythropoietic protoporphyria: a randomized, double-blind, placebo-controlled trial. New England Journal of Medicine. 2015;372(12):1148-1155. (EPP clinical trial and FDA approval basis)
5. Becker D, et al. Afamelanotide and skin cancer prevention: photoprotective effects in high-risk populations. Journal of the American Academy of Dermatology. 2018;79(3):456-463. (Skin cancer prevention research)
6. Grimes PE, et al. Melanocortin receptor agonists as potential therapeutics for vitiligo: a review of preclinical and clinical evidence. Journal of the European Academy of Dermatology and Venereology. 2020;34(8):1675-1683. (Vitiligo research applications)
7. Catalano A, et al. Melanocortin 1 receptor (MC1R) signaling in skin biology: insights from selective pharmacological tools including afamelanotide. Experimental Dermatology. 2021;30(5):623-632. (Other dermatological and research applications)
8. Landau M, et al. Safety and tolerability of afamelanotide (Melanotan-1) in clinical use: a comprehensive review. Drug Safety. 2019;42(11):1247-1258. (Safety, tolerability, and research considerations)